AUPH Quote, Financials, Valuation and Earnings

Lexaria Bioscience Corp. has a net margin of 42.95% compared to Aurinia Pharmaceuticals, Inc.'s net margin of -2178.51%. Aurinia Pharmaceuticals, Inc.'s return on equity of 71.44% beat Lexaria Bioscience Corp.'s return on equity of -189.86%.

Aurinia Pharmaceuticals, Inc. has a consensus price target of $17.00, signalling upside risk potential of 20.14%. On the other hand Lexaria Bioscience Corp. has an analysts' consensus of $3.75 which suggests that it could grow by 455.56%. Given that Lexaria Bioscience Corp. has higher upside potential than Aurinia Pharmaceuticals, Inc., analysts believe Lexaria Bioscience Corp. is more attractive than Aurinia Pharmaceuticals, Inc..

Aurinia Pharmaceuticals, Inc. has a beta of 1.535, which suggesting that the stock is 53.466% more volatile than S&P 500. In comparison Lexaria Bioscience Corp. has a beta of 0.541, suggesting its less volatile than the S&P 500 by 45.863%.

Aurinia Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Lexaria Bioscience Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Aurinia Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Lexaria Bioscience Corp. pays out -- of its earnings as a dividend.

Aurinia Pharmaceuticals, Inc. quarterly revenues are $77.1M, which are larger than Lexaria Bioscience Corp. quarterly revenues of --. Aurinia Pharmaceuticals, Inc.'s net income of $210.8M is higher than Lexaria Bioscience Corp.'s net income of -$1.6M. Notably, Aurinia Pharmaceuticals, Inc.'s price-to-earnings ratio is 6.81x while Lexaria Bioscience Corp.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Aurinia Pharmaceuticals, Inc. is 6.93x versus 24.81x for Lexaria Bioscience Corp.. Usually stocks with elevated PS ratios are considered overvalued.

Oncolytics Biotech, Inc. has a net margin of 42.95% compared to Aurinia Pharmaceuticals, Inc.'s net margin of --. Aurinia Pharmaceuticals, Inc.'s return on equity of 71.44% beat Oncolytics Biotech, Inc.'s return on equity of -635.07%.

Aurinia Pharmaceuticals, Inc. has a consensus price target of $17.00, signalling upside risk potential of 20.14%. On the other hand Oncolytics Biotech, Inc. has an analysts' consensus of $5.54 which suggests that it could grow by 432.25%. Given that Oncolytics Biotech, Inc. has higher upside potential than Aurinia Pharmaceuticals, Inc., analysts believe Oncolytics Biotech, Inc. is more attractive than Aurinia Pharmaceuticals, Inc..

Aurinia Pharmaceuticals, Inc. has a beta of 1.535, which suggesting that the stock is 53.466% more volatile than S&P 500. In comparison Oncolytics Biotech, Inc. has a beta of 0.923, suggesting its less volatile than the S&P 500 by 7.708%.

Aurinia Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Oncolytics Biotech, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Aurinia Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Oncolytics Biotech, Inc. pays out -- of its earnings as a dividend.

Aurinia Pharmaceuticals, Inc. quarterly revenues are $77.1M, which are larger than Oncolytics Biotech, Inc. quarterly revenues of --. Aurinia Pharmaceuticals, Inc.'s net income of $210.8M is higher than Oncolytics Biotech, Inc.'s net income of -$10.5M. Notably, Aurinia Pharmaceuticals, Inc.'s price-to-earnings ratio is 6.81x while Oncolytics Biotech, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Aurinia Pharmaceuticals, Inc. is 6.93x versus -- for Oncolytics Biotech, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

ProMIS Neurosciences, Inc. has a net margin of 42.95% compared to Aurinia Pharmaceuticals, Inc.'s net margin of --. Aurinia Pharmaceuticals, Inc.'s return on equity of 71.44% beat ProMIS Neurosciences, Inc.'s return on equity of -348.3%.

Aurinia Pharmaceuticals, Inc. has a consensus price target of $17.00, signalling upside risk potential of 20.14%. On the other hand ProMIS Neurosciences, Inc. has an analysts' consensus of $64.52 which suggests that it could grow by 162.27%. Given that ProMIS Neurosciences, Inc. has higher upside potential than Aurinia Pharmaceuticals, Inc., analysts believe ProMIS Neurosciences, Inc. is more attractive than Aurinia Pharmaceuticals, Inc..

Aurinia Pharmaceuticals, Inc. has a beta of 1.535, which suggesting that the stock is 53.466% more volatile than S&P 500. In comparison ProMIS Neurosciences, Inc. has a beta of -0.225, suggesting its less volatile than the S&P 500 by 122.489%.

Aurinia Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. ProMIS Neurosciences, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Aurinia Pharmaceuticals, Inc. pays -- of its earnings as a dividend. ProMIS Neurosciences, Inc. pays out -- of its earnings as a dividend.

Aurinia Pharmaceuticals, Inc. quarterly revenues are $77.1M, which are larger than ProMIS Neurosciences, Inc. quarterly revenues of --. Aurinia Pharmaceuticals, Inc.'s net income of $210.8M is higher than ProMIS Neurosciences, Inc.'s net income of -$11.6M. Notably, Aurinia Pharmaceuticals, Inc.'s price-to-earnings ratio is 6.81x while ProMIS Neurosciences, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Aurinia Pharmaceuticals, Inc. is 6.93x versus -- for ProMIS Neurosciences, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Xenon Pharmaceuticals, Inc. has a net margin of 42.95% compared to Aurinia Pharmaceuticals, Inc.'s net margin of -867.29%. Aurinia Pharmaceuticals, Inc.'s return on equity of 71.44% beat Xenon Pharmaceuticals, Inc.'s return on equity of -53.48%.

Aurinia Pharmaceuticals, Inc. has a consensus price target of $17.00, signalling upside risk potential of 20.14%. On the other hand Xenon Pharmaceuticals, Inc. has an analysts' consensus of $56.50 which suggests that it could grow by 29.03%. Given that Xenon Pharmaceuticals, Inc. has higher upside potential than Aurinia Pharmaceuticals, Inc., analysts believe Xenon Pharmaceuticals, Inc. is more attractive than Aurinia Pharmaceuticals, Inc..

Aurinia Pharmaceuticals, Inc. has a beta of 1.535, which suggesting that the stock is 53.466% more volatile than S&P 500. In comparison Xenon Pharmaceuticals, Inc. has a beta of 0.913, suggesting its less volatile than the S&P 500 by 8.665%.

Aurinia Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Xenon Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Aurinia Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Xenon Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.

Aurinia Pharmaceuticals, Inc. quarterly revenues are $77.1M, which are larger than Xenon Pharmaceuticals, Inc. quarterly revenues of --. Aurinia Pharmaceuticals, Inc.'s net income of $210.8M is higher than Xenon Pharmaceuticals, Inc.'s net income of -$105.3M. Notably, Aurinia Pharmaceuticals, Inc.'s price-to-earnings ratio is 6.81x while Xenon Pharmaceuticals, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Aurinia Pharmaceuticals, Inc. is 6.93x versus 462.74x for Xenon Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.